The future of health

Digital health solution for efficient cost reduction

With this digital therapy support via app, which can be downloaded to any smartphone for a fee, patients can better control the handling and efficiency of their inhalers. This is associated with potential savings for the healthcare system in the billions. Active ingredients can be used up to 50% more effectively, the number or visits to doctors and clinics is reduced.

With the Europe-wide labeling as a medical device, the German market has taken a fundamental step towards inclusion in the standard care system in accordance with the new “Digital Health Care Act” (DVG). As a development specialist for highly innovative, digital health solutions for respiratory diseases, VisionHealth thus opens the way to new treatment quality for an estimated 8.9 million respiratory patients in Germany [1],[2].

The Potential

  • A study involving more than 2,000 patients has shown that training in device handling can reduce the exacerbation rate in COPD by 50%[3]
  • Healthcare spending on asthma and COPD worldwide amount to $250 billion per year (in 2015)[4]. Of this, 164 billion is spent on the consequences of inhaler misuse alone[5]

[1] RKI.. 12-Monats-Prävalenz der bekannten chronisch obstruktiven Lungenerkrankung (COPD) in Deutschland.
[2] RKI.. 12-Monats-Prävalenz von Asthma bronchiale bei Erwachsenen in Deutschland.
[3] Molimard et. al. Eur Respir J 2017; 49: 1601794
[4] ERS Whitebook 2017
[5] Roggeri A et al.International Journal of COPD 2016:11597–602

50% of exacerbations can be avoided if patients receive appropriate training in the use of their inhalers[1].


Much more complex than swallowing a pill

In addition to poor adherence to therapy, uncontrolled respiratory diseases are often related to incorrect inhalation technology. Although inhalation therapies can stabilize diseases and alleviate or suppress symptoms, doctors believe that the medications administered in this way are often ineffective. This reflects the fact that the inhalation process, which seems so simple, is in itself very fragile. The ever-new device-drug combinations – both generic drugs and orginators – present both patients and medical staff

with the challenge of operating a complex mix of inhalation devices and different nominal doses and drug combinations. Because of a lack of explanation and practice, many patients make mistakes in operation and a large part of the inhaled dose is deposited only in the mouth and throat, but not in the lungs. However, correct inhalation is usually vital. All that remains of the medication are possible side effects, while the disease becomes more and more unstable.

2020 marks a turning point

Invest and profit

The economic potential motivates the VisionHealth company to develop Kata® on a global scale. Because the profit perspectives are brilliant: Digital health applications are increasingly finding resonance in the medical care of patients. The possibilities to get these (digital) services reimbursed are increasing. In addition, the willingness of patients to pay for medical apps themselves is increasing.

Especially the German health care market has been moving: Thanks to the opportunity provided by the new “Digital Health Care Act” (DVG), the inclusion of medical apps in the standard care system in Germany has been possible since January 2020. This means: reimbursement for health apps, such as Kata®, by all statutory health insurance companies.

The best time to use this momentum is now.

Doing good for good money

Digital High Potential

Studies impressively prove that improved handling of the inhalation systems enables a significantly better therapy success[6],[7],[8].

With the new health app “Kata®”, those affected get a better grip on their treatment of pneumological diseases. The quality of life is improved and everyday restrictions such as coughing attacks, breathing difficulties and sleep deprivation due to incorrect or ineffective inhalation are significantly reduced. Visits to doctors or even emergency hospital stays can be minimized.

[6] Jardim, J. R. & Nascimento, O. A. (2019). The Importance of Inhaler Adherence to Prevent COPD Exacerbations. Medical Sciences (Basel, Switzerland), 7(4).
[7] Morton RW, Elphick HE, Rigby AS, et al. (2017). STAAR: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma Thorax 2017;72:347-354.
[8] Chan, Amy H. Y.; Stewart, Alistair W.; Harrison, Jeff; Camargo, Carlos A.; Black, Peter N.; Mitchell, Edwin A. (2015): The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. In: The Lancet Respiratory Medicine 3 (3), S. 210-219. DOI: 10.1016/S2213-2600(15)00008-9.